Literature DB >> 30622337

Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion.

Ditte Marie Brix1, Siri Amanda Tvingsholm1, Malene Bredahl Hansen1, Knut Bundgaard Clemmensen1, Tiina Ohman2, Valentina Siino3, Matteo Lambrughi4, Klaus Hansen5, Pietri Puustinen1, Irina Gromova6, Peter James7, Elena Papaleo4, Markku Varjosalo2, José Moreira8, Marja Jäättelä9, Tuula Kallunki10,11.   

Abstract

HER2/ErbB2 activation turns on transcriptional processes that induce local invasion and lead to systemic metastasis. The early transcriptional changes needed for ErbB2-induced invasion are poorly understood. Here, we link ErbB2 activation to invasion via ErbB2-induced, SUMO-directed phosphorylation of a single serine residue, S27, of the transcription factor myeloid zinc finger-1 (MZF1). Utilizing an antibody against MZF1-pS27, we show that the phosphorylation of S27 correlates significantly (p < 0.0001) with high-level expression of ErbB2 in primary invasive breast tumors. Phosphorylation of MZF1-S27 is an early response to ErbB2 activation and results in increased transcriptional activity of MZF1. It is needed for the ErbB2-induced expression of MZF1 target genes CTSB and PRKCA, and invasion of single-cells from ErbB2-expressing breast cancer spheroids. The phosphorylation of MZF1-S27 is preceded by poly-SUMOylation of K23, which can make S27 accessible to efficient phosphorylation by PAK4. Based on our results, we suggest for an activation mechanism where phosphorylation of MZF1-S27 triggers MZF1 dissociation from its transcriptional repressors such as the CCCTC-binding factor (CTCF). Our findings increase understanding of the regulation of invasive signaling in breast cancer by uncovering a detailed biological mechanism of how ErbB2 activation can rapidly lead to its invasion-promoting target gene expression and invasion.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30622337      PMCID: PMC6525100          DOI: 10.1038/s41388-018-0653-x

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology.

Authors:  M Egeblad; O H Mortensen; M Jäättelä
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

3.  Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis.

Authors:  Andrea Ivascu; Manfred Kubbies
Journal:  J Biomol Screen       Date:  2006-09-14

4.  PDSM, a motif for phosphorylation-dependent SUMO modification.

Authors:  Ville Hietakangas; Julius Anckar; Henri A Blomster; Mitsuaki Fujimoto; Jorma J Palvimo; Akira Nakai; Lea Sistonen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

5.  Identification of a novel SCAN box-related protein that interacts with MZF1B. The leucine-rich SCAN box mediates hetero- and homoprotein associations.

Authors:  T L Sander; A L Haas; M J Peterson; J F Morris
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

6.  Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation.

Authors:  Takeshi Nagashima; Hidetoshi Shimodaira; Kaori Ide; Takashi Nakakuki; Yukitaka Tani; Kaoru Takahashi; Noriko Yumoto; Mariko Hatakeyama
Journal:  J Biol Chem       Date:  2006-12-01       Impact factor: 5.157

7.  Stability of phosphoprotein as a biological marker of tumor signaling.

Authors:  Amanda F Baker; Tomislav Dragovich; Nathan T Ihle; Ryan Williams; Cecilia Fenoglio-Preiser; Garth Powis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

8.  Regulation of myeloid zinc finger protein 2A transactivation activity through phosphorylation by mitogen-activated protein kinases.

Authors:  Hironori Ogawa; Ayako Murayama; Shigekazu Nagata; Rikiro Fukunaga
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

9.  p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

Authors:  Rosana Sáez; Miguel A Molina; Elizabeth E Ramsey; Federico Rojo; Edward J Keenan; Joan Albanell; Ana Lluch; Javier García-Conde; José Baselga; Gail M Clinton
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

10.  Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.

Authors:  M Tan; P Li; M Sun; G Yin; D Yu
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

View more
  10 in total

Review 1.  Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Ravikumar Amjesh; Bijesh George; M Radhakrishna Pillai
Journal:  Cancer Metastasis Rev       Date:  2020-08-21       Impact factor: 9.264

2.  Age-dependent regulation of cell-mediated collagen turnover.

Authors:  Michael J Podolsky; Christopher D Yang; Carlos Lizama Valenzuela; Ritwik Datta; Steven K Huang; Stephen L Nishimura; Sarah L Dallas; Paul J Wolters; Claude Jourdan Le Saux; Kamran Atabai
Journal:  JCI Insight       Date:  2020-05-21

3.  P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition.

Authors:  Ruth Murrell-Lagnado; Sébastien Roger; Stéphanie Chadet; Jordan Allard; Lucie Brisson; Osbaldo Lopez-Charcas; Roxane Lemoine; Audrey Heraud; Stéphanie Lerondel; Roseline Guibon; Gaëlle Fromont; Alain Le Pape; Denis Angoulvant; Lin-Hua Jiang
Journal:  Oncogene       Date:  2022-04-11       Impact factor: 9.867

Review 4.  Tales from topographic oceans: topologically associated domains and cancer.

Authors:  Moray J Campbell
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

5.  BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine.

Authors:  Deepak Kanojia; Wojciech K Panek; Alex Cordero; Jawad Fares; Annie Xiao; Solomiia Savchuk; Krishan Kumar; Ting Xiao; Katarzyna C Pituch; Jason Miska; Peng Zhang; Kwok-Ling Kam; Craig Horbinski; Irina V Balyasnikova; Atique U Ahmed; Maciej S Lesniak
Journal:  Sci Transl Med       Date:  2020-08-26       Impact factor: 17.956

6.  MZF1 and SCAND1 Reciprocally Regulate CDC37 Gene Expression in Prostate Cancer.

Authors:  Takanori Eguchi; Thomas L Prince; Manh Tien Tran; Chiharu Sogawa; Benjamin J Lang; Stuart K Calderwood
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

7.  METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.

Authors:  Ben Yue; Chenlong Song; Linxi Yang; Ran Cui; Xingwang Cheng; Zizhen Zhang; Gang Zhao
Journal:  Mol Cancer       Date:  2019-10-13       Impact factor: 27.401

8.  Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.

Authors:  Malene Bredahl Hansen; Maria Postol; Siri Tvingsholm; Inger Ødum Nielsen; Tiina Naumanen Dietrich; Pietri Puustinen; Kenji Maeda; Christoffel Dinant; Robert Strauss; David Egan; Marja Jäättelä; Tuula Kallunki
Journal:  Cell Oncol (Dordr)       Date:  2021-05-03       Impact factor: 7.051

9.  MZF1 mediates oncogene-induced senescence by promoting the transcription of p16INK4A.

Authors:  Dan Wu; Hua Tan; Weijun Su; Dongmei Cheng; Guanwen Wang; Juan Wang; Ding A Ma; George M Dong; Peiqing Sun
Journal:  Oncogene       Date:  2021-11-12       Impact factor: 9.867

Review 10.  Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion.

Authors:  Ditte Marie Brix; Knut Kristoffer Bundgaard Clemmensen; Tuula Kallunki
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.